Israel Englander Kal Vista Pharmaceuticals, Inc. Transaction History

Millennium Management LLC

$213 Billion
Q3 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 20,000 shares of KALV stock, worth $266,400. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,000

Previous 90,000 77.78%

Holding current value

$266,400

Previous $1.02 Million 76.3%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$11.56 - $16.01 $20.3 Million - $28.1 Million	1,755,594 Added 515.4%	2,096,223 $25.3 Million
Q2 2025 Aug 14, 2025	BUY	$10.32 - $14.76 $1.47 Million - $2.1 Million	142,424 Added 71.86%	340,629 $3.85 Million
Q1 2025 May 15, 2025	BUY	$7.4 - $12.6 $1.47 Million - $2.5 Million	198,205 New	198,205 $2.29 Million
Q1 2024 May 15, 2024	BUY	$11.07 - $16.04 $213,972 - $310,037	19,329 New	19,329 $229,000
Q2 2023 Aug 14, 2023	SELL	$7.73 - $10.57 $407,896 - $557,757	-52,768 Reduced 65.39%	27,935 $251,000

Q1 2023 May 15, 2023	SELL	$6.3 - $8.39 $2.49 Million - $3.32 Million	-395,548 Reduced 83.05%	80,703 $634,000
Q4 2022 Feb 14, 2023	SELL	$4.2 - $14.24 $7,169 - $24,307	-1,707 Reduced 0.36%	476,251 $3.22 Million
Q3 2022 Nov 14, 2022	BUY	$9.85 - $16.83 $3.72 Million - $6.36 Million	377,641 Added 376.45%	477,958 $6.94 Million
Q2 2022 Aug 15, 2022	BUY	$8.16 - $15.1 $678,659 - $1.26 Million	83,169 Added 485.01%	100,317 $987,000
Q1 2022 May 16, 2022	BUY	$11.2 - $16.97 $192,057 - $291,001	17,148 New	17,148 $253,000
Q4 2021 Feb 14, 2022	SELL	$12.36 - $18.28 $453,797 - $671,150	-36,715 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$17.11 - $24.49 $628,193 - $899,150	36,715 New	36,715 $641,000
Q1 2021 May 17, 2021	SELL	$14.69 - $42.57 $423,027 - $1.23 Million	-28,797 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$12.88 - $19.47 $437,675 - $661,610	-33,981 Reduced 54.13%	28,797 $547,000
Q3 2020 Nov 16, 2020	BUY	$9.83 - $13.99 $150,556 - $214,270	15,316 Added 32.27%	62,778 $790,000
Q2 2020 Aug 14, 2020	BUY	$6.75 - $12.89 $320,368 - $611,785	47,462 New	47,462 $574,000
Q1 2020 May 14, 2020	SELL	$5.8 - $18.56 $163,258 - $522,426	-28,148 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$10.31 - $17.81 $143,607 - $248,075	13,929 Added 97.96%	28,148 $501,000
Q3 2019 Nov 14, 2019	BUY	$11.6 - $21.67 $50,158 - $93,701	4,324 Added 43.7%	14,219 $164,000
Q2 2019 Aug 15, 2019	SELL	$18.44 - $30.89 $6.95 Million - $11.6 Million	-376,730 Reduced 97.44%	9,895 $219,000
Q2 2019 Aug 14, 2019	BUY	$18.44 - $30.89 $5.35 Million - $8.96 Million	290,155 Added 300.77%	386,625 $14.6 Million
Q1 2019 May 14, 2019	BUY	$16.51 - $31.1 $1.59 Million - $3 Million	96,470 New	96,470 $2.76 Million
Q4 2018 Feb 14, 2019	SELL	$16.21 - $24.06 $843,584 - $1.25 Million	-52,041 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$8.0 - $22.11 $311,392 - $860,609	38,924 Added 296.74%	52,041 $1.15 Million
Q2 2018 Aug 14, 2018	SELL	$7.79 - $9.84 $1.68 Million - $2.13 Million	-216,131 Reduced 94.28%	13,117 $107,000
Q1 2018 May 15, 2018	SELL	$9.22 - $12.35 $67,637 - $90,599	-7,336 Reduced 3.1%	229,248 $2.17 Million
Q4 2017 Feb 14, 2018	BUY	$6.8 - $13.54 $1.61 Million - $3.2 Million	236,584	236,584 $2.31 Million

Others Institutions Holding KALV

# of Institutions

156

Shares Held

59.9M

Call Options Held

1.21M

Put Options Held

865K

View Full List

About KalVista Pharmaceuticals, Inc.

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $328M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

More about KALV

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account